Mental health analytics and screening company Medibio is seeing increased interest in its ilumen™ product, driven by large numbers of isolated individuals in response to COVID-19.
The ASX-listed health company’s ilumen™ technology combines a number of objective indicators, such as sleep quality and hours of exercise with self-reported analysis of emotional status to provide an effective screening tool for mental health and anxiety levels.
The revolutionary health company has seen unprecedented interest in the technology from existing clients as well as potential new partners, with all corporate clients able to offer ilumen to a wide number of staff.
These businesses then receive feedback based on the percentage of staff that are reporting increased anxiety and depression, effectively allowing companies to gauge how effectively they are managing their staff’s mental health. All individual user’s data remains anonymous.
Business already utilising ilumen include global food services conglomerate Compass Group, a British multinational mining company and Stantec, a global engineering, design and professional services firm.
Commenting on the surge of interest in mental health screening Senior Vice President of Corporate Health at Medibio, Jennifer Solitario said:
COVID-19 has changed everything about life and work as we know it. Attention to mental health in the workplace is more important now than ever before.
“We at Medibio are seeing a heightened interest and demand for ilumen™ both in Australia and internationally, and we are responding accordingly.
“Medibio’s ilumen™ team here in Australia and the USA are working to ensure that ilumen™ is made available to those corporations and their employees as easily and as efficiently as possible”.
The scalable nature of the company’s technology allows Medibio to manage the increased uptake of its mental health product as well as operate in many locations across the globe.
